4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Total Non-Current Liabilities data on file, last reported at $60.9 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 32.99% year-over-year to $60.9 million in Q1 2026; TTM through Mar 2026 was $60.9 million, a 32.99% increase from a year earlier, with the FY2025 full-year figure at $60.9 million, up 22.84% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $60.9 million, roughly flat from $60.9 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for FDMT reached as high as $60.9 million in Q1 2026 and fell as low as $25.4 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $39.4 million across 5 years, with a median of $31.7 million in 2023.
• Across the five-year window, Total Non-Current Liabilities surged 144.84% in 2022 and fell 12.02% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $30.5 million in 2022, then climbed by 3.95% to $31.7 million in 2023, then jumped by 56.45% to $49.6 million in 2024, then rose by 22.84% to $60.9 million in 2025, then climbed by 0.06% to $60.9 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $60.9 million in Q1 2026, $60.9 million in Q4 2025, and $54.7 million in Q3 2025.